Sarah Chaney gives an in-depth look at the Salix-Valeant acquisition - how analysts and investors can affect decision-making and potentially drive poor behavior.
Sarah Chaney
Advertisement
Sarah Chaney is a business reporting student at the University of North Carolina at Chapel Hill.
Articles by Sarah Chaney
Advertisement
Latest Updated Articles
- The Salix-Valeant Acquisition: "It’s Just a Game"
Published: July 7th 2015 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
How Do Global Pharma Growth Strategies Differ from Domestic Strategies?
2
Raising Biomarker Awareness
3
The 49th State: Q&A with Mark Mikhael
4
How Can Harvard Business School Students and Alumni Prepare for Their Long-Term Career Journeys in an Accelerating AI-Focused Society?
5
